Investors & Media Company Overview UNITY Biotechnology is developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest Presentation Download News Releases October 12, 2020 UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema September 15, 2020 UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
October 12, 2020 UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
September 15, 2020 UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
